Top Story
-
FDA Submits Interim Peptide Compounding Policy For White House Review
FDA’s ‘Interim Access Policy for Compounding Using Certain Peptides’ is now pending OMB review, following the July 2026 PCAC meeting on BPC-157, TB-500, and other substances.
Latest News
-
FDA Submits Interim Peptide Compounding Policy For White House Review
-
CBS News Lab Tests Find Bacterial Contamination in Products Sold as Retatrutide
-
PSM Petitions FDA to Block Compounding of Seven Unapproved Peptides
-
American Academy of Peptide Medicine Meets FDA, HHS on Interim Peptide Access Policy
